Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
David A SallmanMonzr M Al MalkiAdam S AschEunice S WangJoseph G JurcicTerrence J BradleyIan W FlinnDaniel A PollyeaSuman KambhampatiTiffany N TanakaJoshua F ZeidnerGuillermo Garcia ManeroDeepa JeyakumarRami S KomrokjiJeffrey LancetHagop M KantarjianLin GuYajia ZhangAnderson TanMark ChaoCarol O'HearGiridharan RamsinghIndu LalParesh VyasNaval G DaverPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
mutations. A phase III trial of magrolimab/placebo + azacitidine is ongoing (ENHANCE: NCT04313881).